Hematopoietic recovery rates following high-dose chemotherapy in autologous blood stem cell recipients have been shown, in part, to be dependent on the source and quantity of hematopoietic stem cells infused. Mobilized blood stem cell quantity (identified by the surface expression of the CD34 antigen) has been demonstrated in multiple studies to be the strongest predictor of days to hematopoietic recovery (ie platelets and neutrophils) in autologous blood stem cell recipients. Additionally, data from four large studies confirm that prompt and sustained hematopoietic recovery will occur in the majority of patients treated with high-dose chemotherapy if a stem cell dose у5 × 10 6 /kg is administered. However, multiple aphereses are needed in the majority of patients to achieve these optimal stem cell doses. Problems associated with multiple aphereses procedures include hypocalcemia, anemia, thrombocytopenia, infection, thrombosis, increased costs, and malignant cell contamination of the apheresis product. Recent data indicate that less differentiated (eg CD33 − ) stem and progenitor cells result in both early and sustained hematopoietic recovery in bone marrow and blood stem cell recipients. Future trials using new growth factors such as stem cell factor (which has been shown to increase CD34 + /CD33 − cell mobilization), as well as improvements in purging strategies are needed to ensure prompt, sustained, and malignant-cell-free engraftment for the majority of autologous blood stem cell recipients.
The kinetics of autologous hematopoietic recovery in cancer patients treated with high-dose chemotherapy is variable but, in part, appears to be dependent on the source and quantity of hematopoietic stem and progenitor cells (stem cells) infused. [1] [2] [3] [4] Autologous blood-derived stem cells (mobilized with hematopoietic growth factors or with single-and multi-agent chemotherapy and growth factors) have supplanted bone marrow-derived stem cells for use in hematopoietic reconstitution after high-dose chemotherapy because of more rapid hematopoietic recovery, decreased morbidity, and lower total costs. [5] [6] [7] [8] [9] Correspondence: Dr AL Pecora, Hackensack University Medical Center, 5 Summit Avenue, Hackensack, NJ 07601, USA Hematopoietic recovery rates following high-dose chemotherapy in autologous blood stem cell recipients have been shown to be a function of patient diagnosis, amount of prior therapy, and conditioning regimen used. 4, 10 Surrogate measures of the hematopoietic reconstitutive capacity of blood-derived stem cells have been identified and include number of colony-forming units granulocyte-macrophage (CFU-GM), mononuclear cells, and total nucleated cells. However, mobilized blood stem cell quantity (identified by the surface expression of the CD34 antigen) has been demonstrated in multiple studies to significantly correlate with CFU-GM quantity and to be the strongest predictor of days to hematopoietic recovery in autologous blood stem cell recipients. 3, 4, 11, 12 Hematopoietic stem cell phenotype during self-renewal and differentiation
The life cycle of a hematopoietic stem cell is characterized by its ability for self-renewal and differentiation. 13 Hematopoietic cells derived from blood and administered to patients following high-dose chemotherapy have been termed 'stem cells' despite the fact that they contain distinct populations of true stem cells and differentiated progenitor cells. 1, 13, 14 Multiparameter flow cytometry has enabled investigators to differentiate early stem cells and multipotent progenitor cells from unipotent progenitor cells committed to the myeloid lineage by assessment of cell surface antigen expression (Figure 1 + cells lacking the CD33 antigen have extensive proliferative potential, giving rise to long-term culture-initiating cells (LTC-IC), and in vivo have been shown to circulate in the blood of untreated healthy donors. 14, 15 In contrast, CD34
+ cells that co-express CD33 generate more differentiated cells with limited in vitro potential, such as CFU-GM.
The two-phase theory of hematopoietic stem cell engraftment
Hematopoietic recovery following stem cell infusion after high-dose chemotherapy occurs as a result of hematopoietic stem cell self-renewal and differentiation. Jones et al 16 conducted pioneering studies in mice to elucidate the role stem cell subsets, classified by their extent of differentiation, have in hematopoietic recovery following myeloablative therapy. In these experiments, marrow from male B6D 2 F 1 mice was infused into female B6D 2 F 1 mice following sublethal irradiation (myeloablative). Upon engraftment, chimeric mice were used as donors with serial transplants being performed in consecutive myeloablated B-6 females until engraftment failure was observed. Early hematopoietic recovery was lost after four to five serial transplants; this was thought to be the result of the depletion of stem cells with rapid engrafting potential. Somewhat unexpectedlyafter only three serial transplants and despite early hematopoietic recovery with male cells -transplanted mice eventually reverted to female marrow. Jones theorized that differentiated hematopoietic stem cells recovered rapidly but not completely after each serial transplant, enabling early hematopoietic recovery on subsequent transplants until depletion of this pool of cells. Early undifferentiated hematopoietic cells were depleted sooner due to a slower recovery rate, and therefore, durable engraftment potential was lost prior to losing early hematopoietic recovery. In other experiments, the time between serial transplants was increased. As a result, durable hematopoietic recovery was observed on subsequent serial transplants and not lost prior to losing early recovery, suggesting that the delay between transplants enabled undifferentiated hematopoietic progenitor cells to recover in number. Jones concluded that hematopoietic stem cell recovery following myeloablative therapy occurred in two phases: early but transient hematopoietic recovery was the result of expansion of differentiated progenitor cells, which was followed in time by expansion of early, less differentiated progenitor and stem cells that support late and sustained hematopoietic engraftment.
In humans, the infusion of blood-derived stem cells following high-dose chemotherapy routinely results in prompt and sustained hematopoietic recovery. This process, however, is quite complex and the rate of recovery may be affected by several variables, including patient diagnosis, number and type of hematopoietic stem cells infused, conditioning regimen, and peritransplant medication and complications. [1] [2] [3] [4] It should not be surprising that hematopoietic recovery is variable and appears to be somewhat independent of hematopoietic stem cell dose. This has led to a number of investigators (beginning with Siena et al) performing studies to determine what effects the number and type of infused stem cells have on engraftment rates. 1 Siena was the first to demonstrate that hematopoietic stem cells expressing the CD34 antigen were mobilized into the blood with chemotherapy and/or hematopoietic growth factors. These cells were readily classified into early (less differentiated) and late (more differentiated) progenitors by determining the absence or presence, respectively, of the CD33 antigen using flow cytometry. In Siena's original studies, most patients were found to mobilize both early and late CD34 + cells and the relative percentage of each subset mobilized appeared to vary among patients and by the mobilization regimen used. By 1991, Siena et al, using multivariate analysis, determined that the best predictor of the rate of early hematopoietic engraftment was the quantity of CD34 + 33 + (late) stem cells infused. Furthermore, Siena believed that CD34 + 33 − cell replication and differentiation was also responsible for the second phase of engraftment (late but sustained recovery). A subsequent series of clinical studies performed by Roberts et al 17 appeared to confirm these conclusions. Here, patients with acute myelogenous leukemia underwent autologous marrow transplantation using marrow treated with an anti-CD33 monoclonal antibody and complement. Hematopoietic recovery rates were compared between this group and patients with acute lymphocytic leukemia whose marrow was treated with anti-CD6 or anti-CD10 and complement. A significant delay in hematopoietic recovery was observed in the anti-CD33-treated marrow group; however, no delay was noted in the other treatment groups. Seemingly, removal of CD33 + progenitor cells from the marrow resulted in delayed hematopoietic recovery due to the absence of early repopulating cells. Late and sustained recovery was thought to occur because CD33 − progenitors
were not affected, supporting the observations of Siena and of Jones.
Predictors of hematopoietic recovery
Uni-and multivariate analyses have been used in several large clinical trials to determine predictors of the rate of hematopoietic recovery in autologous blood stem cell recipients. A recent analysis of 375 consecutive autologous blood stem cell transplant patients revealed CD34 + stem cell dose to be a highly significant (P = 0.001) predictor of hematopoietic recovery rates. 18 However, other variables, including patient diagnosis, conditioning regimen, and peritransplant complications and medication appear to alter the effect of CD34 + stem cell dose on hematopoietic recovery. 3, 4, 18 Regardless, the relationship between CD34 + stem cell dose and the rate of hematopoietic recovery has been greatly clarified by recent studies. In an analysis of 600 patients, Weaver et al observed that as the CD34 + stem cell dose was increased from 2.5 to 5 × 10 6 /kg, the median time to achieve an absolute neutrophil count of 500 cells/l dropped significantly. 4 Furthermore, using Kaplan-Meier estimates, the number of days required for 95% of the patient population to achieve an absolute neutrophil count of 500 cells/l dropped strikingly as the CD34 + stem cell dose was increased from 2.5 to 5 × 10 6 /kg. Days to platelet transfusion independence was also noted in this study to drop significantly as the CD34 + stem cell dose increased to 5 × 10 6 /kg (Figure 2 ). Weaver correctly concluded that to optimize the rate of hematopoietic recovery and to have the /kg), days to neutrophil and platelet recovery dropped significantly. 19 In fact, multiple blood stem cell dose thresholds that affect hematopoietic recovery rates and transfusion requirements are now well characterized. In our study, days to neutrophil and platelet recovery were significantly greater (P = 0.001) in patients who received a total CD34
+ blood stem cell dose of р2.5 vs Ͼ 2.5, р5 vs Ͼ5, and р10 vs Ͼ10 × 10 6 /kg (Table 1) . 18 In contrast, days to neutrophil and platelet recovery were similar in patients who received a total CD34
+ cell dose of 10 or Ͼ10 × 10 6 /kg. These data suggest that a minimum of 7 days to achieve a neutrophil count of 500 cells/l and 12 days for 50 000 platelets/l will be observed after high-dose chemotherapy regardless of the blood stem cell dose.
CD34
+ subset cell dose and its relationship to hematopoietic recovery and transfusion requirements Recent analyses performed by several groups on much larger series of patients, however, indicate that less differentiated progenitors (CD33 − ) are responsible for both early and sustained hematopoietic recovery in humans, refuting the two-phase theory of engraftment. 18, [20] [21] [22] In our initial analysis of 68 patients treated with highdose chemotherapy and autologous blood stem cell support, CD34 + 33 − cell dose was noted to inversely correlate with days to recovery of 500 and 1000 neutrophils/l (P Ͻ 0.001), 50 000 platelets/l (P = 0.003), and days to hospital discharge (P Ͻ 0.001). 18 Subsequent studies by Dercksen et al 21 and Copelan et al 22 showed CD34 + 33 − cell dose to inversely correlate with neutrophil recovery and, in the Dercksen analysis, platelet transfusion independence. In each of these analyses, the number of patients studied was small (n Ͻ 81), so other variables purported to influence engraftment kinetics, such as patient characteristics, extent of prior treatment, and conditioning regimen could not be appropriately assessed. Therefore, in a series of 375 consecutive patients who received high-dose chemotherapy and autologous blood stem cell transplant, our group performed Cox proportional hazards regression analysis to determine which factors most reliably predict days to neutrophil and platelet recovery and transfusion requirements. Variables analyzed included patient age, diagnosis, mobilization regimen, pre-apheresis patient blood counts, as well as mononuclear cell, total CD34 + , CD34 and CD34 + 33 − cell dose (P Ͻ 0.005) were identified as the only positive significant predictors of days to neutrophil (500 cells/l) and platelet (50 000 cells/l) recovery (Table 2 ). CD34 + 33 + cell dose did not correlate with days to hematopoietic recovery nor predict red blood cell and platelet transfusion requirements. Independent of CD34 + stem cell dose, patient diagnosis had a clear effect on hematopoietic recovery rates in autologous blood stem cell recipients ( Table 2 ). Similar to total CD34 + blood stem cell dosing, multiple CD34 + 33 − cell dose thresholds were identified (Table 3) . Moreover, CD34
+ 33 − cell dose was found to be the only significant predictor of red blood cell (P Ͻ 0.0001) and single-donor platelet transfusion requirements (P Ͻ 0.0001). In this series, a subgroup of 55 patients received a seemingly adequate total CD34
+ cell dose (median 3.6 × 10 
38
− cell dose (a component of CD34 + 33 − cells) was the strongest predictor of days to achieve 1000 neutrophils/l in allogeneic bone marrow recipients (r = −0.30; P = 0.001). CD34 +
− cell dose was also found to significantly correlate with days to achieve 20 000 platelets/l in autologous bone marrow recipients (r = −0.301; P = 0.004) and allogeneic bone marrow recipients (r = −0.241; P = 0.07). In addition, a preliminary analysis performed by Stiff et al 24 on autologous hematopoietic recovery in high-dose chemotherapy patients rescued with ex vivo expanded bone marrow found lineage-negative (CD34 + 38 − 33 − ) cell dose to be S11 Table 3 Blood stem cell dose thresholds the only significant predictor of neutrophil and platelet recovery rates. Collectively, these data indirectly but strongly support the notion that less differentiated (CD33 − ) stem and progenitor cells result in both early and sustained hematopoietic recovery in bone marrow and blood stem cell recipients. This has now been confirmed with direct evidence demonstrated recently in a trial reported by Archimbaud et al. 25 They observed both rapid and sustained engraftment with selected autologous blood CD34
+ Thy-1 + Lin − hematopoietic stem cells (devoid of differentiated progenitor cells) in myeloma patients treated with melphalan and total body irradiation.
Problems with multiple apheresis procedures
The data from four large studies confirm that prompt and sustained hematopoietic recovery will occur in the majority of patients treated with high-dose chemotherapy if a stem cell dose of у5 × 10 6 /kg is administered. 3, 4, 18, 19 To attain this cell dose, however, requires multiple apheresis procedures in most patients. Problems associated with multiple apheresis procedures have been identified and include hypocalcemia, anemia, thrombocytopenia, infection, and thrombosis (due to the large indwelling catheter used). Increased costs are also a factor. To quantify the expense of multiple aphereses, Glaspy developed an economic model that revealed a cost of $2266 for each apheresis procedure subsequent to the first apheresis day. Malignant cell contamination of the apheresis product is another concern; Brugger et al 26 were the first to identify malignant cells in the apheresis product. Later, Brenner and Deisseroth independently conducted gene-marking experiments which proved that malignant cells infused with a blood stem cell product contribute to disease relapse. 27, 28 The likelihood of malignant cell contamination of an apheresis product appears to be a function of the number of apheresis procedures performed. Kahn, in a study of patients with metastatic breast cancer, showed that as the number of apheresis procedures increase, the risk of tumor cell contamination also increases. 29 In this analysis, a 5.4% incidence of tumor cell contamination in a group of patients requiring one apheresis procedure was observed. This incidence increased strikingly as the number of apheresis procedures increased: 15.4% incidence for patients requiring two aphereses, 30.4% for those requiring three, 30.7% for those requiring four, and 42% for those requiring more than four (P Ͻ 0.001).
A variety of methods to purge potentially contaminated stem cell grafts have been explored; purging theoretically would allow continued aphereses until an ideal blood stem cell dose (ie у5 × 10 6 /kg) is obtained. CD34
+ cell selection using monoclonal antibodies to bind and collect blood stem cells expressing the CD34 antigen (which is not expressed by malignant cells) has been studied. 30 An approach being pioneered by Stiff et al using the Aastrom Biosciences cell production system (Aastrom Biosciences, Austin, TX, USA) to expand bone marrow stem cells ex vivo has been demonstrated by Lundell et al to result in passive purging of contaminating breast cancer cells. 31 In support of these purging approaches is the finding that CD34
+ -selected stem cells result in similar rates of cell dose-dependent hematopoietic recovery compared with non-selected products. Furthermore, while the use of ex vivo expanded products has resulted in delays in neutrophil and platelet recovery, they have been acceptable. 32 Unfortunately, the use of CD34 + cell selection as well as ex vivo expansion has yet to demonstrate consistent total removal of contaminating tumor cells. Moreover, these technologies add substantially to the cost and processing time of stem cell products.
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Conclusion
Engraftment following high-dose chemotherapy is the result of early undifferentiated stem and progenitor cell self-renewal and differentiation. The rate of engraftment is clearly dependent, in part, on the number and type of stem cells infused. Increasing the stem cell dose will decrease days to neutrophil and platelet recovery and transfusion requirements. However, this benefit is currently offset by the complications and expense associated with multiple apheresis procedures and the potential increased risk of malignant cell contamination. Future trials using new growth factors such as stem cell factor, which has been shown to increase CD34 + cell mobilization and the relevant subset (CD33 − ), 33 as well as improvements in purging strategies are needed to ensure prompt, sustained, and malignant cell-free engraftment for the majority of autologous blood stem cell recipients.
